Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $3.48 USD
Change Today -0.20 / -5.43%
Volume 48.6K
CDXS On Other Exchanges
As of 8:10 PM 07/28/15 All times are local (Market data is delayed by at least 15 minutes).

codexis inc (CDXS) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/15/15 - $5.65
52 Week Low
07/29/14 - $1.89
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for CODEXIS INC (CDXS)

codexis inc (CDXS) Related Businessweek News

View More BusinessWeek News

codexis inc (CDXS) Details

Codexis, Inc. develops biocatalysts for the pharmaceutical and fine chemicals markets in the United States and internationally. The company offers Codex biocatalyst panels and kits to pharmaceutical companies that are engaged in drug development and the marketing of approved drugs to allow them to screen and identify possible enzymatic manufacturing processes for their drug candidates and their marketed products. It also provides enzyme screening services and enzyme optimization services; and supplies enzymes, pharmaceutical intermediates, and active pharmaceutical ingredients. In addition, the company develops biocatalysts for use in the fine chemicals market, including food, animal feed, agricultural chemicals, and flavors and fragrances. It sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. Codexis, Inc. was founded in 2002 and is headquartered in Redwood City, California.

91 Employees
Last Reported Date: 03/6/15
Founded in 2002

codexis inc (CDXS) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $592.0K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $171.9K
Chief Administrative Officer, Executive Vice ...
Total Annual Compensation: $385.4K
Senior Vice President of Research & Developme...
Total Annual Compensation: $257.4K
Compensation as of Fiscal Year 2014.

codexis inc (CDXS) Key Developments

Codexis, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Provides Earnings Guidance for Second Half and Year 2015

Codexis, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the period, the company reported total revenues of $6,798,000 against $7,074,000 a year ago. Loss from operations was $5,529,000 against $6,396,000 a year ago. Loss before income taxes was $5,550,000 against $6,505,000 a year ago. Net loss was $5,562,000 or $0.14 per basic and diluted share against $6,375,000 or $0.17 per basic and diluted share a year ago. Net loss - Non-GAAP was $2,875,000 or $0.07 per basic and diluted share against $4,046,000 or $0.11 per basic and diluted share a year ago. The company affirmed its financial guidance for 2015. For the period, the company expects total revenues of $39 million to $42 million, representing growth of 10% to 19% over 2014. This revenue guidance assumes recognizing a $6.5 million milestone related to the company's non-exclusive licensing agreement with GSK, which is expected toward the end of 2015. Gross margins as a percent of total revenue are expected to be in the range of 70% to 75%. The company expects stronger growth in the second half of 2015 compared with the first half.

Codexis, Inc., Annual General Meeting, Jun 10, 2015

Codexis, Inc., Annual General Meeting, Jun 10, 2015., at 09:00 Pacific Standard Time. Location: executive offices at 400 Penobscot Drive. Agenda: To elect each of Kathleen S. Glaub, Bernard J. Kelley and John J. Nicols to board of directors for a three-year term expiring at the 2018 annual meeting of stockholders or until their respective successors are duly elected and qualified or their earlier resignation or removal; to ratify the selection of BDO USA, LLP as independent registered public accounting firm for the fiscal year ending December 31, 2015; and to transact such other business as may properly come before the annual meeting.

Codexis, Inc. to Report Q1, 2015 Results on May 07, 2015

Codexis, Inc. announced that they will report Q1, 2015 results at 4:30 PM, US Eastern Standard Time on May 07, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CDXS:US $3.48 USD -0.20

CDXS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BASF SE €77.73 EUR +0.93
Cambrex Corp $46.66 USD +0.96
Koninklijke DSM NV €51.68 EUR +0.38
Novozymes A/S kr348.00 DKK +2.90
Takasago International Corp ¥530.00 JPY -5.00
View Industry Companies

Industry Analysis


Industry Average

Valuation CDXS Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CODEXIS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at